The proportion of patients achieving a weight reduction of
≥5% with dapagliflozin at 104 weeks was 23.8% (95% CI 19.6,
27.9) and with glipizide it was 2.8% (95% CI 1.2, 4.4), resulting
in a dapagliflozin versus glipizide difference at 104 weeks of 21.0
percentage points (95% CI 16.5, 25.5).